Milestones

April 2008 CPDC announces funding from federal and provincial governments and officially opens labs and offices at McMaster University.


Jan. 2009 Over 150 leading experts from academia, industry, health care and government institutions attend CPDC’s first Annual Probe Development Workshop to learn about the future of molecular imaging and its impact on patient care. CPDC introduces Investigator Sponsored Research Program (ISRP) to help researchers bring discoveries to commercial use.


Jan. 2009 CPDC brings together Ontario Institute for Cancer Research, Hamilton Health Science and GE Healthcare to conduct the world’s first clinical trial of a cutting-edge molecular breast imaging technology that could dramatically improve detection and staging of breast cancer.


June 2009 John Valliant delivers prestigious Henry N. Wagner lectureship,  keynote address, at the 2009 annual conference of the Society of Nuclear Medicine.


Oct. 2009 Funding is awarded to CPDC to develop 123I-Iodohippuric Acid, an alternative agent for Technetium-99m-labeled probes used for imaging kidney function.


Nov. 2009 CPDC completes major upgrades to the radiopharmacy and implements good manufacturing practices and full quality system in accordance with Health Canada regulatory requirements.


Dec. 2009 The first patient dose of 18F-Glucovision® (18F-FDG) is manufactured and shipped from CPDC’s newly renovated radiopharmacy.


Dec. 2009 CPDC provides 18F-Sodium Fluoride as substitute imaging agent for bone scans during Technetium-99m isotope shortage


Feb. 2010 CPDC is first in Ontario to produce 18F-Fluorothymidine (18F-FLT) for a clinical trial program. This probe, which is used to assess tumour proliferation, could play an important role in quickly evaluating the effectiveness of chemotherapy.


April 2010 McMaster University and CPDC are awarded $22 million in funding from Ontario Knowledge Infrastructure Program to begin construction of new research labs, office space, the installation of a second cyclotron and upgrades to the nuclear reactor.


June 2010 The radiopharmacy implements a fully automated production process for Glucovision—doubling product yield, reducing production time by more than 60% and ensuring consistent product quality.


June 2010 Second Annual Probe Development Workshop draws over 150 attendees. Topics focus on probe translation, drug development, emerging probes and oncology.


Sept. 2010 CPDC files its first patent application for a new Microreactor Technology­­­­­—a faster more efficient and more cost-effective process to attach isotopes to probes.


Jan. 2011 A new process is implemented to manufacture 18F-FLT, providing higher yields, greater consistency in product quality and extended shelf life.


Jan. 2011 The Government of Canada announces that CPDC, along with a national team of experts, will work collaboratively to develop alternative, non-reactor based sources of medical isotopes from cyclotrons, or particle accelerators. Backup or supplementary isotope sources will help provide Canadians with a secure, long-term supply and mitigate the effects of isotope shortages on health care.


Jan. 2011 Responding to increasing production volumes and market need, CPDC opens a microbiology lab. Solely focused on sterility testing of products and production environment, the lab accelerates testing turnaround time and assures the highest product quality for customers.


May 2011 CPDC provides 18F-Fluoroazomycin Arabinoside (18F-FAZA) for Ontario’s first clinical trial to assess tumour hypoxia and help physicians determine most effective treatment.


June 2011 Third Annual Probe Development Workshop draws 200 attendees and focuses on imaging technologies for cancer, Alzheimer’s disease and Parkinson’s disease.


June 2011 University Health Network and CPDC announce CanProbe, a joint venture to develop and manufacture new diagnostic and therapeutic radiopharmaceuticals to meet growing Canadian and global demand.


Aug. 2011 With more than 50 employees, CPDC moves in to 28,000 sq. ft. of additional lab and office space at McMaster’s newly expanded Nuclear Research Building. The $22- million project also includes a new cyclotron for research and manufacturing.